Lung Cancer Translational and Emerging Therapies
Coordonnateurs : Pandya Kishan J., Brahmer Julie R., Hidalgo Manuel
Molecular Biology of Lung Cancer as the Basis for Targeted Therapy. Early Clinical Trial Design Issues: Patient Populations, End Points, and Barriers. Antiangiogenic Therapy for Lung Cancer: Small-Molecule Inhibitors. Antiangiogenic Therapy for Lung Cancer: Antibodies and Other Novel Agents. Epidermal Growth Factor Receptor Inhibition in Non-Small Cell Lung Cancer. Epidermal Growth Factor Receptor Targeted Therapy-Markers of Sensitivity and Response. Other Novel Targeted Therapies in Lung Cancer. Lung Cancer Vaccines. Advances in Chemoradiation Treatment of Locoregionally Advanced Non-Small Cell Lung Cancer. Advances in the Treatment of Brain Metastases. Recent Advances in Imaging for Lung Cancer
Date de parution : 06-2020
15.2x22.9 cm
Date de parution : 05-2007
15.2x22.9 cm
Thèmes de Lung Cancer :
Mots-clés :
EGFR TKIs; EGFR TKI; cancer-related deaths; PD; antineoplastic agents; ISEL Study; small-cell lung cancer; EGFR Immunostaining; monoclonal antibodies; High EGFR Gene Copy Number; chemotherapy; EGFR Mutation; EGFR Gene Copy Number; Harbor EGFR Mutation; EGFR Gene; Phase Ii; Phase Ii Study; Adjuvant WBRT; ISEL Trial; EGFR IHC; Fish Positive Patient; RPA Class; Brain Metastases; Phase Ii Trial; Full Dose Chemotherapy; Stage Ii; Hyperfractionated Radiation; Increase EGFR Gene Copy Number; Refractory NSCLC; Gy Fractions